Fragment-based approaches to enzyme inhibition
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Fragment-based approaches have provided a new paradigm for small-molecule drug discovery. The methodology is complementary to high-throughput screening approaches, starting from fragments of low molecular complexity and high ligand efficiency, and building up to more potent inhibitors. The approach, which depends heavily on a number of biophysical techniques, is now being taken up by more groups in both industry and academia. This article describes key aspects of the process and highlights recent developments and applications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Small-molecule inhibitors of protein–protein interactions: progressing towards the dream
Arkin, M. R., & Wells, J. A. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1343 · Cited by 1,705 · cited 1×
“Fragments are now being used to address increasingly challenging targets, such as protein–protein interactions [53] and RNA [54].”
Background
Cited by
Modifying enzyme activity and selectivity by immobilization
Rodrigues, R. C., Ortiz, C., Berenguer-Murcia, Á., Torres, R., & Fernández-Lafuente, R. (2013) · Chem. Soc. Rev. · doi:10.1039/c2cs35231a · Cited by 1,810
The spectrum of latent tuberculosis: rethinking the biology and intervention strategies
Barry, C. E., Boshoff, H. I., Dartois, V., Dick, T., Ehrt, S., Flynn, J., Schnappinger, D., Wilkinson, R. J., & Young, D. (2009) · Nature Reviews Microbiology · doi:10.1038/nrmicro2236 · Cited by 1,422
The rise of fragment-based drug discovery
Murray, C. W., & Rees, D. C. (2009) · Nature Chemistry · doi:10.1038/nchem.217 · Cited by 791
Recent Developments in Fragment-Based Drug Discovery
Congreve, M., Chessari, G., Tisi, D., & Woodhead, A. J. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm8000373 · Cited by 611
Fragment-Based Approaches in Drug Discovery and Chemical Biology
Scott, D. E., Coyne, A. G., Hudson, S. A., & Abell, C. (2012) · Biochemistry · doi:10.1021/bi3005126 · Cited by 460
Self-citation
Metadata
- Authors
- Ciulli, A., & Abell, C.
- Venue
- Current Opinion in Biotechnology
- Publisher
- Elsevier BV
- Published
- 2007-12
- Volume
- 18
- Issue
- 6
- Pages
- 489-496
- ISSN
- 0958-1669 (ISSN-L)
- OpenAlex
- W1998673246
- Cited by
- 109
- References
- 1
- FWCI
- 0.58
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.